Literature DB >> 1973616

The CD4 molecule and HIV infection.

D R Klatzmann1, J S McDougal, P J Maddon.   

Abstract

CD4 (T4), a glycoprotein expressed largely on the surface of cells in the immune system, serves as the receptor for the human immunodeficiency virus, HIV. The isolation of the CD4 gene has permitted an analysis of the structure of CD4 and its role in both HIV infection and the immune response. Recently, new classes of CD4-based therapeutics have been generated that interfere with HIV attachment to target cells. Soluble CD4 proteins and CD4-based chimeric molecules are currently undergoing clinical evaluation in HIV-infected individuals.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1973616

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN： 0893-5300


  11 in total

1.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

Authors:  V Litwin; K A Nagashima; A M Ryder; C H Chang; J M Carver; W C Olson; M Alizon; K W Hasel; P J Maddon; G P Allaway
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Human alpha1-acid glycoprotein binds to CCR5 expressed on the plasma membrane of human primary macrophages.

Authors:  A Atemezem; E Mbemba; R Vassy; H Slimani; L Saffar; L Gattegno
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

4.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

5.  Characterization and anti-HIV properties of CD 4-coated red blood cells.

Authors:  T Idziorek; V Chams; D Klatzmann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Carbohydrate binding properties of the envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  M Haidar; N Seddiki; J C Gluckman; L Gattegno
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

7.  Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; H Rochat; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population.

Authors:  M Caruso; D Klatzmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

9.  Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.

Authors:  E A Berger; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

10.  Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.